Advertisement

Topics

Companies Related to "Biofrontera Aktie kaufen bereits hohe Dynamik rfte 2018" [Most Relevant Company Matches] RSS

20:28 EST 17th December 2017 | BioPortfolio

Here are the most relevant search results for "Biofrontera Aktie kaufen bereits hohe Dynamik rfte 2018" found in our extensive corporate database of over 50,000 company records.

Showing "Biofrontera Aktie kaufen bereits hohe Dynamik rfte 2018" Companies, all 20

Relevant

Biofrontera AG

Biofrontera AG is a biopharmaceutical company specializing in the development of drugs for the treatment of dermatological and inflammatory diseases. The Company has three product candidates in clinical development for four different clinical indications. The most advanced products are BF-200 ALA (Phase IIb/III) for actinic keratosis and condyloma; and BF-derm 1 (Phase II) for chronic, antihistami...


Amazon de

Amazon.de öffnete seine virtuellen Tore in Deutschland im Oktober 1998. Ziel war es von jeher, das kundenorientierteste Unternehmen der Welt zu sein, bei dem Kunden alles finden, was sie online kaufen wollen -- zum günstigsten Preis. Amazon.de und Verkäufer, die ihre Produkte bei Amazon listen, bieten Millionen neuer und gebrauchter Produkte in den Bereichen Bücher, English Books, Musik, DVD, ...

Merckle GmbH

Die Merckle GmbH zählt zu den führenden Arzneimittelherstellern Europas. Zusammen mit dem Tochterunternehmen ratiopharm GmbH, der meistverwendeten und meistverordneten Arzneimittelmarke in Deutschland und eines der führenden Generikaunternehmen in Europa, agiert Merckle/ratiopharm als eine Pharmaunternehmensgruppe mit internationaler Ausrichtung. Die Firmengruppe ist zu 100 Prozent im Familienb...


BioTime, Inc. 

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell and drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells...

Probably Relevant

Moving Mountains for Multiple Myeloma

Moving Mountains for Multiple Myeloma is supported by the MMRF, CURE Media Group and Takeda. In addition to the Mt. Fuji 2017 climb, Moving Mountains for Multiple Myeloma treks planned for 2018 include a trip to Everest Base Camp in March. Funds raised by the Moving Mountains for Multiple Myeloma endeavors will go directly to research, supporting the MMRF ...

AstraZeneca GmbH

Forschungsförderpreis – Imaging in Psychiatrie und Psychotherapie Der Preis wird während der DGPPN-Mitgliederversammlung, die im R ahmen des diesjährigen DGPPN-Kongresses in Berlin stattfindet, verliehen und soll für einen Forschungsaufenthalt im Ausland genutzt werden. Ziel ist es, junge Wissenschaftler aus allen Fachbereichen, die bereits erste Erfahrungen mit Bildgebungsmethoden im Berei...

Landos Biopharma, Inc.

Landos Biopharma, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, locally-acting small molecule targeting inflammatory bowel disease (IBD) that is expected to enter clinical testing for Crohn’s...

Life Sciences Ontario

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, focused on becoming the leader in the targeted alpha therapy field. Fusion, which is a spin out from McMaster University’s Centre for Probe Development and Commercialization (CPDC), exploits its unique expertise in linking medical isotopes to targeting molecules to cre...

FluGen Inc.

FluGen, Inc. is a clinical stage vaccine company focused on improving the breadth and effectiveness of influenza vaccines. The Company’s technology comes from the laboratory of Dr. Yoshihiro Kawaoka at the University of Wisconsin, Madison. It’s lead product candidate, RedeeFlu™ is a universal flu vaccine which is based on the knowledge that a ...

Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clin...

Die Pacific Health Corporation

Unter dem Namen Pacific Health Corporation betreibt die Asklepios-Gruppe in Kalifornien, USA, sechs Krankenhäuser. Diese verfügen mit einem eigenen Krankenversicherungsprogramm über eine aktive Managed Care Gruppe. In einem Verbund mit etwa 800 Ärzten und 30 Krankenhäusern werden Patienten im Großraum Los Angeles versorgt. In der Mehrzahl sind die Versicherungsnehmer sogenannte Medicare-Pati...

LETI Pharma GmbH

Laboratorios LETIVor rd. 80 Jahren gründete Prof. Pedro Domingo Sanjuán in Spanien das Experimentallabor für therapeutische Immunologie. LETI steht für: 'Laboratorio Experimental de Terapéutica Immunógena'. Das junge Unternehmen machte sich einen Namen als Pionier bei der Entwicklung von Antibiotika und Impfstoffen. Bereits in den frühen 40er Jahren begann es mit der Entwicklung von Präpar...

IMAC Regeneration Centers

IMAC Regeneration Centers was created to provide options in healthcare that do not require surgery or prescription pain medication. IMAC provides alternative treatments for joint replacement and spinal fusion and has never written an opioid prescription in company history. Patients range from accomplished athletes maintaining optimal performance, to elderl...

NovioSense

NovioSense BV was founded in July 2012 as a joint venture between NovioTech BV in Nijmegen (NL) and Fraunhofer IMS in Duisburg (DE). The company has raised financing from regional seed fund PPM Oost and Health Innovation Fund as well as in the form of a European Subsidy as part of the InterReg IV A Telemedicine Project. The aim of the company is to develop...

Trellis Bioscience

Monoclonal antibody technology was the research breakthrough of the 1980’s. With the discovery by Milstein and Kohler in Cambridge, England, Hybritech became the first company dedicated to the production of monoclonal antibodies, commercializing the first diagnostic tests and leading to two subsequent companies that furthered monoclonal antibody development, GenProbe and IDEC. The use of monoclo...

ACGT ProGenomics AG

Die ACGT ProGenomics AG ist das weltweit erste Unternehmen, dem es gelungen ist, einen blut-basierten Früherkennungstest für die Alzheimer-Erkrankung zu entwickeln. Mit AlzAlert, einem sensitiven, raschen und kostengünstigen Testverfahren für eine Verdachtsdiagnose zur Alzheimer-Erkrankung, hat die ACGT ProGenomics AG ein innovatives und weltmarktfähiges diagnostisches Produkt geschaffen, des...

iVeena Delivery Systems, Inc.

iVeena Delivery Systems, Inc. (iVeena) is a privately held biopharmaceutical company that develops innovative ophthalmology products. iVeena utilizes a proprietary intracapsular drug delivery platform to enhance a medication’s ocular bioavailability to anterior and posterior eye segments. The lead product delivers dexamethasone to treat post-cataract ...

Harpoon Therapeutics, Inc.

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T-cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created a novel T-cell recruiting d...

Panasonic Corporation of North America

Based in Secaucus, NJ, Panasonic Corporation of North America provides a broad line of digital and other electronics products and services for consumer, business and industrial use. The company is the principal North American subsidiary of Osaka, Japan-based Panasonic Corporation (NYSE: PC), and the hub of Panasonic’s U.S. branding, marketing, sales, ...

Allergy Therapeutics

Allergy Therapeutics®. (AT) is a Europe-based specialty pharmaceutical company focused upon the treatment and prevention of allergy. AT has an existing sales base of approximately £19m/€27m per annum, an MHRA-approved manufacturing capability and an established sales and marketing infrastructure in several major European markets. In addition, the Company has a number of novel compounds which h...


More From BioPortfolio on "Biofrontera Aktie kaufen bereits hohe Dynamik rfte 2018"

Quick Search
Advertisement
 

Corporate Database Quicklinks